Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk profile of pociredir in sickle cell disease (SCD) ―